外泌体在心肌梗死治疗中的研究新进展

doi:10.11958/20230440

天津医药 ›› 2023, Vol. 51 ›› Issue (9): 1016-1019.doi: 10.11958/20230440

外泌体在心肌梗死治疗中的研究新进展

侯永波¹^,²(), 余骏马², 朱海娟³^,^△()

1.皖南医学院麻醉学院（邮编241002）
2.安徽医科大学第三附属医院（合肥市第一人民医院）麻醉科
3.安徽医科大学附属妇幼保健院麻醉科

收稿日期:2023-03-27 修回日期:2023-04-19 出版日期:2023-09-15 发布日期:2023-09-13
通讯作者: △E-mail：35880762@qq.com
作者简介:侯永波（1998），男，硕士研究生在读，主要从事靶向治疗心肌缺血再灌注损伤方面研究。E-mail：2399534874@qq.com
基金资助:
国家自然科学基金资助项目(82100315)

New research progress of exosomes in the treatment of myocardial infarction

HOU Yongbo¹^,²(), YU Junma², ZHU Haijuan³^,^△()

1. College of Anesthesiology-Wannan Medical College, Wuhu 241002, China
2. Department of Anesthesiology, the Third Affiliated Hospital of Anhui Medical University, Hefei First People's Hospital
3. Department of Anesthesiology, Maternal and Child Health Hospital Affiliated to Anhui Medical University

Received:2023-03-27 Revised:2023-04-19 Published:2023-09-15 Online:2023-09-13
Contact: △E-mail：35880762@qq.com

侯永波, 余骏马, 朱海娟. 外泌体在心肌梗死治疗中的研究新进展[J]. 天津医药, 2023, 51(9): 1016-1019.

HOU Yongbo, YU Junma, ZHU Haijuan. New research progress of exosomes in the treatment of myocardial infarction[J]. Tianjin Medical Journal, 2023, 51(9): 1016-1019.

摘要/Abstract

摘要：

心肌梗死是致死率较高的疾病之一，且疾病后期进展常导致慢性心力衰竭的发生，探索新的治疗方法对于心肌梗死的预后十分重要。外泌体是由细胞或组织液释放的直径为30~150 nm的纳米级囊泡，其囊泡内携带着来自亲代细胞分泌的特异DNA、RNA、蛋白质、脂质和代谢废物等物质，其作为心肌梗死的潜在治疗方法在基础实验中早已被证实。就不同细胞组织来源的外泌体、工程化外泌体以及外泌体细胞膜融合策略在心肌梗死治疗中的研究进展进行综述，为外泌体在临床上的应用提供科学证据。

关键词: 心肌梗死, 外泌体, 间质干细胞, 成纤维细胞, 巨噬细胞, 膜融合, 微RNAs

Abstract:

Myocardial infarction is one of the most lethal diseases, and the progression of the disease often leads to the occurrence of chronic heart failure. Therefore, it is very important to explore new treatment methods for the prognosis of myocardial infarction. Exosomes are nanoscale vesicles with a diameter of 30-150 nm released from cells or tissue fluid. The vesicles carry specific DNA, RNA, proteins, lipids, metabolic waste and other substances secreted by parental cells. As a potential treatment for myocardial infarction, it has long been confirmed in basic experiments. This article reviews the latest research progress of exosomes from different cells and tissues, engineered exosomes and exosome cell membrane fusion strategies in the treatment of myocardial infarction, and provides scientific evidence for the clinical application of exosomes.

Key words: myocardial infarction, exosomes, mesenchymal stem cells, fibroblasts, macrophages, membrane fusion, microRNAs

中图分类号:

R541

参考文献 32

[1]	CHENG L, HILL A F. Therapeutically harnessing extracellular vesicles[J]. Nat Rev Drug Discov, 2022, 21(5):379-399. doi:10.1038/s41573-022-00410-w.
[2]	COLOMBO M, RAPOSO G, THÉRY C. Biogenesis,secretion,and intercellular interactions of exosomes and other extracellular vesicles[J]. Annu Rev Cell Dev Biol, 2014, 30:255-289. doi:10.1146/annurev-cellbio-101512-122326.
[3]	TANG J, JIN L, LIU Y, et al. Exosomes derived from mesenchymal stem cells protect the myocardium against ischemia/reperfusion injury through inhibiting pyroptosis[J]. Drug Des Devel Ther, 2020, 14:3765-3775. doi:10.2147/DDDT.S239546.
[4]	SUN X H, WANG X, ZHANG Y, et al. Exosomes of bone-marrow stromal cells inhibit cardiomyocyte apoptosis under ischemic and hypoxic conditions via miR-486-5p targeting the PTEN/PI3K/AKT signaling pathway[J]. Thromb Res, 2019, 177:23-32. doi:10.1016/j.thromres.2019.02.002.
[5]	SUN J, SHEN H, SHAO L, et al. HIF-1α overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis[J]. Stem Cell Res Ther, 2020, 11(1):373. doi:10.1186/s13287-020-01881-7.
[6]	BU L, JIANG X, MARTIN-PUIG S, et al. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages[J]. Nature, 2009, 460(7251):113-117. doi:10.1038/nature08191.
[7]	YOUN S W, LI Y, KIM Y M, et al. Modification of cardiac progenitor cell-derived exosomes by miR-322 provides protection against myocardial infarction through Nox2-dependent angiogenesis[J]. Antioxidants(Basel), 2019, 8(1):18. doi:10.3390/antiox8010018.
[8]	XIAO J, PAN Y, LI X H, et al. Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4[J]. Cell Death Dis, 2016, 7(6):e2277. doi:10.1038/cddis.2016.181.
[9]	VICENCIO J M, YELLON D M, SIVARAMAN V, et al. Plasma exosomes protect the myocardium from ischemia-reperfusion injury[J]. J Am Coll Cardiol, 2015, 65(15):1525-1536. doi:10.1016/j.jacc.2015.02.026.
[10]	LUO Z, HU X, WU C, et al. Plasma exosomes generated by ischaemic preconditioning are cardioprotective in a rat heart failure model[J]. Br J Anaesth, 2023, 130(1):29-38. doi:10.1016/j.bja.2022.08.040.
[11]	WANG B, CAO C, HAN D, et al. Dysregulation of miR-342-3p in plasma exosomes derived from convalescent AMI patients and its consequences on cardiac repair[J]. Biomed Pharmacother, 2021, 142:112056. doi:10.1016/j.biopha.2021.112056.
[12]	TURNER A, AGGARWAL P, MATTER A, et al. Donor-specific phenotypic variation in hiPSC cardiomyocyte-derived exosomes impacts endothelial cell function[J]. Am J Physiol Heart Circ Physiol, 2021, 320(3):H954-H968. doi:10.1152/ajpheart.00463.2020.
[13]	LIU N, XIE L, XIAO P, et al. Cardiac fibroblasts secrete exosome microRNA to suppress cardiomyocyte pyroptosis in myocardial ischemia/reperfusion injury[J]. Mol Cell Biochem, 2022, 477(4):1249-1260. doi:10.1007/s11010-021-04343-7.
[14]	LUO H, LI X, LI T, et al. microRNA-423-3p exosomes derived from cardiac fibroblasts mediates the cardioprotective effects of ischaemic post-conditioning[J]. Cardiovasc Res, 2019, 115(7):1189-1204. doi:10.1093/cvr/cvy231.
[15]	ZHU F, CHEN Y, LI J, et al. Human umbilical cord mesenchymal stem cell-derived exosomes attenuate myocardial infarction injury via miR-24-3p-Promoted M2 macrophage polarization[J]. Adv Biol(Weinh), 2022, 6(11):e2200074. doi:10.1002/adbi.202200074.
[16]	WANG C, ZHANG C, LIU L, et al. Macrophage-derived miR-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury[J]. Mol Ther, 2017, 25(1):192-204. doi:10.1016/j.ymthe.2016.09.001.
[17]	LIU S, CHEN J, SHI J, et al. M1-like macrophage-derived exosomes suppress angiogenesis and exacerbate cardiac dysfunction in a myocardial infarction microenvironment[J]. Basic Res Cardiol, 2020, 115(2):22. doi:10.1007/s00395-020-0781-7.
[18]	DAI Y, WANG S, CHANG S, et al. M2 macrophage-derived exosomes carry microRNA-148a to alleviate myocardial ischemia/reperfusion injury via inhibiting TXNIP and the TLR4/NF-κB/NLRP3 inflammasome signaling pathway[J]. J Mol Cell Cardiol, 2020, 142:65-79. doi:10.1016/j.yjmcc.2020.02.007.
[19]	LONG R, GAO L, LI Y, et al. M2 macrophage-derived exosomes carry miR-1271-5p to alleviate cardiac injury in acute myocardial infarction through down-regulating SOX6[J]. Mol Immunol, 2021, 136:26-35. doi:10.1016/j.molimm.2021.05.006.
[20]	CHEN C, CAI S, WU M, et al. Role of cardiomyocyte-derived exosomal microRNA-146a-5p in macrophage polarization and activation[J]. Dis Markers, 2022, 2022:2948578. doi:10.1155/2022/2948578.
[21]	XU R, ZHANG F, CHAI R, et al. Exosomes derived from pro-inflammatory bone marrow-derived mesenchymal stem cells reduce inflammation and myocardial injury via mediating macrophage polarization[J]. J Cell Mol Med, 2019, 23(11):7617-7631. doi:10.1111/jcmm.14635.
[22]	DENG S, ZHOU X, GE Z, et al. Exosomes from adipose-derived mesenchymal stem cells ameliorate cardiac damage after myocardial infarction by activating S1P/SK1/S1PR1 signaling and promoting macrophage M2 polarization[J]. Int J Biochem Cell Biol, 2019, 114:105564. doi:10.1016/j.biocel.2019.105564.
[23]	HAZAN-HALEVY I, ROSENBLUM D, WEINSTEIN S, et al. Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes[J]. Cancer Lett, 2015, 364(1):59-69. doi:10.1016/j.canlet.2015.04.026.
[24]	GALLET R, DAWKINS J, VALLE J, et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction[J]. Eur Heart J, 2017, 38(3):201-211. doi:10.1093/eurheartj/ehw240.
[25]	HU C M, FANG R H, WANG K C, et al. Nanoparticle biointerfacing by platelet membrane cloaking[J]. Nature, 2015, 526(7571):118-121. doi:10.1038/nature15373.
[26]	VAN DER MEEL R, FENS M H, VADER P, et al. Extracellular vesicles as drug delivery systems:Lessons from the liposome field[J]. J Control Release, 2014, 195:72-85. doi:10.1016/j.jconrel.2014.07.049.
[27]	WEI Z, CHEN Z, ZHAO Y, et al. Mononuclear phagocyte system blockade using extracellular vesicles modified with CD47 on membrane surface for myocardial infarction reperfusion injury treatment[J]. Biomaterials, 2021, 275:121000. doi:10.1016/j.biomaterials.2021.121000.
[28]	YAO J, HUANG K, ZHU D, et al. A minimally invasive exosome spray repairs heart after myocardial infarction[J]. ACS Nano, 2021, 15(7):11099-11111. doi:10.1021/acsnano.1c00628.
[29]	LI Q, SONG Y, WANG Q, et al. Engineering extracellular vesicles with platelet membranes fusion enhanced targeted therapeutic angiogenesis in a mouse model of myocardial ischemia reperfusion[J]. Theranostics, 2021, 11(8):3916-3931. doi:10.7150/thno.52496.
[30]	SPRINGER T A. von Willebrand factor,Jedi knight of the bloodstream[J]. Blood, 2014, 124(9):1412-1425. doi:10.1182/blood-2014-05-378638.
[31]	VALENTIJN K M, EIKENBOOM J. Weibel-palade bodies:a window to von Willebrand disease[J]. J Thromb Haemost, 2013, 11(4):581-592. doi:10.1111/jth.12160.
[32]	ZHANG N, SONG Y, HUANG Z, et al. Monocyte mimics improve mesenchymal stem cell-derived extracellular vesicle homing in a mouse MI/RI model[J]. Biomaterials, 2020, 255:120168. doi:10.1016/j.biomaterials.2020.120168.

外泌体在心肌梗死治疗中的研究新进展

New research progress of exosomes in the treatment of myocardial infarction

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高攀, 谢冰歆, 周赞东, 刘彤. 慢性肾脏病循环中FGF23对心房纤维化的促进作用[J]. 天津医药, 2024, 52(9): 917-923.
[2]	贾维宁, 鲍亚玲, 雷慧, 殷晓宁. 夏枯草提取物对脓毒症小鼠炎症反应和腹腔巨噬细胞的影响[J]. 天津医药, 2024, 52(9): 930-935.
[3]	肖小丽, 谢瑶, 龙志. 丙型肝炎患者血清miR-155、miR-205-5p水平变化及诊断价值[J]. 天津医药, 2024, 52(9): 967-970.
[4]	周丽芸, 王岩, 董本超, 杨培川, 申佳慧, 马剑雄, 马信龙. 干细胞机械敏感性对抗骨质疏松症研究进展[J]. 天津医药, 2024, 52(8): 877-881.
[5]	杨睿, 魏琼, 孙逸坤, 赵梦竹, 程序, 刘梦华, 张冬梅. 缺氧H9c2来源外泌体对HUVEC增殖、迁移和成管能力的影响[J]. 天津医药, 2024, 52(7): 714-719.
[6]	赵斌, 赵志虎, 骆巍, 马剑雄, 马信龙. 大鼠周围神经损伤后外周血内皮祖细胞动员及相关因子含量变化[J]. 天津医药, 2024, 52(5): 459-462.
[7]	肖锦亮, 汪威廉, 但家朋. 瑞马唑仑调节EPAC1/RAP1信号通路对急性心肌梗死大鼠心肌损伤的影响[J]. 天津医药, 2024, 52(5): 475-479.
[8]	吴纪昆, 徐榕笛, 许景涵, 王乐, 丛洪良. 6种常见模型评分对NSTEMI患者远期预后预测价值的验证和比较[J]. 天津医药, 2024, 52(5): 541-547.
[9]	满君, 高艳艳, 宋龙飞, 高福生. LncRNA FEZF1-AS1靶向调控miR-200c-3p对人肺成纤维细胞生物学行为的影响[J]. 天津医药, 2024, 52(3): 231-236.
[10]	李晓卫, 高静, 刘寅, 高明东, 肖健勇. 早期与晚期支架内血栓致4b型急性心肌梗死患者临床结局比较[J]. 天津医药, 2024, 52(3): 290-296.
[11]	钟家帅, 冯玉梅. 小鼠骨髓和脂肪间充质干细胞定向分化能力的比较研究[J]. 天津医药, 2024, 52(2): 129-135.
[12]	张晓旭, 杨文奇. 沙库巴曲缬沙坦治疗AMI后射血分数中间值心力衰竭的疗效研究[J]. 天津医药, 2024, 52(2): 177-181.
[13]	高光仁, 冯连荣, 付金国, 郭润, 牛和平, 李凤鹏, 张倩玉, 张军. 急性心肌梗死合并胸腔积液患者的心肌损伤特点及对远期预后的影响[J]. 天津医药, 2024, 52(2): 197-200.
[14]	王鑫瑶, 杨惠, 李冰冰. 间充质干细胞在子宫内膜异位症中的研究进展[J]. 天津医药, 2024, 52(2): 215-219.
[15]	缪春波, 许迎春, 常以芳. 根皮苷通过下调miR-125a-5p减轻缺氧/复氧诱导的H9C2细胞氧化应激和凋亡[J]. 天津医药, 2024, 52(12): 1233-1238.